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Abstract
Epithelial ovarian cancer (EOC) is the second most com-
mon genital malignancy in women and is the most lethal 
gynecological malignancy, with an estimated five-year 
survival rate of 39%. Despite efforts to develop an effec-
tive ovarian cancer screening method, 60% of patients still 
present with advanced disease. Comprehensive manage-
ment using surgical cytoreduction to decrease the tumor 
load to a minimum, and intraperitoneal chemotherapy to 
eliminate microscopic disease on peritoneal surface, has 
the potential to greatly improve quality of life and to have 
an impact on survival in ovarian cancer patients. Despite 
achieving clinical remission after completion of initial treat-
ment, most patients (60%) with advanced EOC will ulti-
mately develop recurrent disease or show drug resistance; 
the eventual rate of curability is less than 30%. Given the 
poor outcome of women with advanced EOC, it is impera-
tive to continue to explore novel therapies.
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INTRODUCTION
Epithelial ovarian cancer is the second most common 
genital malignancy in women and it is the most lethal 
gynecological malignancy, with an estimated five-year sur-
vival rate of  39%[1]. Despite efforts to develop an effective 
ovarian cancer screening method, 60% of  patients still 
present with advanced (Stages Ⅲ-Ⅳ) disease[2]. CA-125 
serum levels, transvaginal ultrasound, and pelvic examina-
tion have long been thought to be potentially effective 
screening tools. However, none of  them have proved ef-
fective in decreasing mortality from ovarian cancer.
An epithelial ovarian tumor arises from the serosal 
lining of  the ovary, which communicates with the 
serosal lining of  the abdomino-pelvic cavity known as 
the peritoneum. As a consequence of  tumor growth, 
malignant cells exfoliate and shed, becoming free floating 
in the peritoneal fluid. They typically implant in the pelvis 
and subdiaphramatic recesses owing to gravity and the 
incumbent position. This spread of  the tumor within 
the peritoneum is termed peritoneal carcinomatosis, and 
it is a typical feature of  cancer spread in patients with 
primary advanced or recurrent epithelial ovarian cancers. 
Intraoperatively, it is characterized by the presence of  
macroscopic tumor nodules of  variable sizes and consis-
tencies that can coalesce to form plaques or masses within 
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the abdominopelvic cavity. Tumor dissemination from the 
peritoneal cavity into the pleural cavity might also occur 
through the lymphatic lacunae within the diaphragmatic 
peritoneum. This results in severe pleural effusion which 
compromises lung and cardiac function. It typically 
presents with vague gastrointestinal symptoms, such as 
abdominal bloating, distension, weight loss, and fatigue. 
Due to the heterogeneity and lack of  specificity of  these 
early clinical symptoms, diagnosis is often delayed. In the 
final stages of  this disease, patients suffer from severe 
symptoms of  profound anorexia, dyspnea, and severe 
pain from malignant bowel obstruction, abdominal 
distension for ascites, and pleural effusion as a result of  
the extensive burden of  tumors that characterizes this fatal 
deterioration. In the past, peritoneal carcinomatosis was 
considered a terminal condition and patients were treated 
with palliatively. However, despite extensive dissemination 
within the abdominopelvic cavity, this condition is now 
considered a loco-regional disease. 
In many patients, the natural history of  ovarian cancer 
is similar to gastrointestinal tumors with peritoneal surface 
dissemination. In fact, in both cases, the late consequences 
of  peritoneal carcinomatosis are debilitating ascites and 
intestinal obstruction. With the full knowledge of  the 
natural history of  this progressive disease, the targets of  the 
treatment should be both the peritoneal surface diffusion 
and the systemic metastases. There is no doubt that the 
eradication of  the peritoneal surface components of  this 
disease would be a major contribution to the overall, and 
disease-free, survival, as well as improving the quality of  life 
of  ovarian cancer patients. Comprehensive management 
using surgical cytoreduction to decrease the tumor load to 
a minimum, and intraperitoneal chemotherapy to eliminate 
microscopic disease on peritoneal surface, has the potential 
to greatly improve quality of  life and have an impact on 
survival in these patients. In the setting of  primary disease, 
optimal cytoreductive surgery (residual tumor < 1 cm) and 
platinum-based chemotherapy have been established as the 
most important determinants of  clinical outcome. 
THE CLINICAL AND BIOLOGICAL 
RATIONALE FOR MAXIMAL 
CYTOREDUCTION IN OVARIAN CANCER
More than 20 years after Griffiths’ major paper[3], a recent 
meta analysis by Bristow et al[4] examined the effect of  
maximal cytoreductive surgery on survival in advanced 
ovarian cancer. The author concluded that maximal 
cytoreduction was one of  the most powerful reasons of  
cohort survival for patients with this disease. Eisenkop 
et al[5] found that cytoreduction had a more significant 
influence on survival than the extent of  metastatic 
disease observed before surgery. Incorporating extensive 
upper abdominal debulking procedures with standard 
pelvic cytoreduction (rectosigmoid resection, peritoneal 
stripping, diaphragm stripping, extensive bowel resection, 
splenectomy, partial gastrectomy, and resection of  liver 
and kidney) not only significantly improved the disease-
free survival rate of  patients left with optimal residual 
disease (85%), but also led to a significant improvement in 
overall survival.
The apparent value of  primary cytoreductive sur-
gery is based on the following reasons: (1) Surgery is 
thought to remove resistant clones of  tumor cells and 
thus decreases the likelihood of  the early onset of  drug 
resistance; (2) The removal of  large masses likely to be 
associated with poorly vascularized areas of  tumors sup-
posedly improves the probability of  delivering adequate 
drug doses to the remaining cancer cells; (3) The higher 
growth fraction in better vascularized small masses 
enhances the effect of  chemotherapy; (4) In principle, 
smaller masses require fewer cycles of  chemotherapy 
and thus decrease the likelihood of  drug resistance; (5) 
Removal of  bulky disease theoretically enhances the im-
mune system; (6) The patients feel better after removal 
of  ascites and large tumor masses, particularly from the 
omentum; and (7) Surgery alleviates the associated nau-
sea and satiety these patients feel.
PREOPERATIVE SELECTION CRITERIA 
TO EVALUATE THE INTRAPERITONEAL 
DIFFUSION OF THE DISEASE
Residual disease after primary surgery is one of  the most 
important prognostic factors in advanced ovarian cancer 
patients. However, a certain percentage of  women, rang-
ing between 25% and 90%[6,7], are not suitable for opti-
mal cytoreduction after exploratory laparotomy, and are 
treated by neoadjuvant chemotherapy. To preoperatively 
identify patients with unresectable tumors, which can be 
spared an unnecessary exploratory laparotomy, several 
approaches have been attempted, including the evalua-
tion of  CA-125 serum levels and the radiological assess-
ment of  tumor spread. However, the accuracy of  these 
parameters has been unsatisfactory, and has been limited 
by the retrospective nature of  the studies and the highly 
variable rates of  optimal cytoreduction in different se-
ries[7]. In this context, a genetic analysis by microarrays 
has been attempted to identify some biologic character-
istics underlying the possibility of  optimal debulking, re-
sulting in a low predictive accuracy[8]. Laparoscopy is well 
known for offering a direct and magnified vision of  the 
peritoneal cavity and a better view of  the upper abdo-
men. It allows the pathological assessment of  the disease 
without an open surgical procedure, with a shorter op-
erating time, and better results in terms of  postoperative 
morbidity. Indeed, it has been demonstrated to be an 
effective procedure for restaging early ovarian cancer[9-11]. 
A recent pilot study by Fagotti et al[12] demonstrated that 
laparoscopy is an adequate and reliable procedure for the 
assessment of  the chances of  optimal cytoreduction (RT 
< 1 cm) in clinically advanced ovarian cancer patients. 
Since then, other investigators have been confirming the 
role of  laparoscopy in the evaluation of  the possibility 
of  achieving optimal residual disease in the same clini-
cal subset[13,14]. Subsequently, in a consecutive prospec-
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tive series of  113 advanced ovarian cancer patients, the 
presence of  omental cake, peritoneal and diaphragmatic 
extensive carcinomatosis, mesenteric retraction, bowel 
and stomach infiltration, and spleen and/or liver su-
perficial metastasis were investigated by laparoscopy. 
Each parameter received a score based on a specificity > 
75%, positive predictive value (PPV), negative predictive 
value (NPV) > 50%, and accuracy > 60% with respect 
to the chances of  achieving an optimal cytoreduction. 
By summing the scores relative to the presence of  every 
aforementioned parameter, an overall laparoscopic value 
for each patient (total predictive index value = PIV) was 
calculated. Sensitivity, specificity, PPV, NPV, and accu-
racy with respect to optimal RT were calculated for each 
PIV. Finally, the authors concluded that the proposed 
laparoscopic model appears a reliable and flexible tool 
to predict optimal cytoreduction in advanced ovarian 
cancer. More recently, this model has been applied in a 
different center from that in which it was developed[15]. 
The results from this study have shown that even when 
utilized in a different setting of  patients, the laparoscopic 
PIV can identify advanced ovarian cancer cases that are 
likely to be suitable for optimal debulking. 
SURGICAL PROCEDURES IN THE 
MANAGEMENT OF ADVANCED OVARIAN 
CANCER
Worldwide, there are more than two hundred thousand 
new cases of  ovarian cancer diagnosed annually, ac-
counting for about 4% of  female cancers. 
In 1994, the National Institutes of  Health[16] con-
vened a 14-member panel of  experts in the management 
of  ovarian cancer to generate a consensus statement of  
recommendations. The panel concluded that: “Adequate 
and complete surgical intervention is a mandatory pri-
mary therapy for ovarian cancer, permitting precise stag-
ing, accurate diagnosis, and optimal cytoreduction. The 
procedure is best conducted by a qualified gynecologic 
oncologist, when there is a high probability of  ovarian 
cancer. All women with suspected ovarian cancer should 
be offered a preoperative consultation with a gynaeco-
logic oncologist”. During the past decade, compelling 
published work has accumulated to lend support to 
these consensus recommendations. These reports show 
that initial surgery for ovarian cancer is most appropri-
ately done by gynaecological oncologists, preferably in 
centers with expertise in the multidisciplinary manage-
ment of  this disease. Engelen et al[17] recently described 
a population-based observational study of  patterns of  
care for 680 women with ovarian cancer in the northern 
Netherlands. The patients were treated between 1994 
and 1997. The main objective of  the study was the effect 
of  surgery performed by a gynaecological oncologist on 
the quality of  surgery and survival outcome compared 
with surgery by a general gynaecologist without subspe-
cialty training. In all disease stages, patients received sur-
gical treatment according to prevailing surgical guidelines 
more frequently when operated on by a gynaecological 
oncologist. The risk of  death for patients who did not 
have surgery according to accepted guidelines was al-
most twice that for patients who had surgery according 
to the guidelines. In this study, patients with stage Ⅰ/Ⅱ 
disease were more likely to be staged by gynaecological 
oncologists than general gynaecological surgeons, result-
ing in a more accurate assignment of  disease stage and 
administration of  adjuvant treatment. For patients with 
stage Ⅲ disease, five-year survival was 32% when the 
guidelines were followed and 11% when guidelines were 
not (hazard ratio 1.97, 95% CI: 1.45-2.68, P < 0.001). 
Furthermore, more patients with stage Ⅲ disease had 
complete debulking (24% vs 12%) and reduced residual 
disease (< 2 cm) (62% vs 45%) by a gynaecological on-
cologist when compared to a gynaecologist. These data, 
as well as similar population-based studies, lend support 
to three main conclusions about the delivery of  cancer 
care services for women with suspected ovarian can-
cer[18-21]: (1) the disparity in survival outcomes according 
to the specialty of  operating surgeon, after confounding 
factors have been accounted for, supports the long-held 
hypothesis that the surgically-attained maximum diam-
eter of  residual disease is inversely proportional to sur-
vival outcome. Consequently, primary cytoreductive sur-
gery offers the best opportunity for achieving extended 
survival and should be considered the standard of  care 
for women with advanced-stage epithelial ovarian can-
cer; (2) the consistent and positive effect of  a surgeons’ 
specialty on survival provides irrefutable evidence that 
surgical care in ovarian cancer should be concentrated 
in centers with gynaecological oncologists. These surgi-
cal subspecialists have the necessary expertise to stage 
patients with early-stage disease as well as to perform 
the cytoreductive surgery necessary to achieve minimal 
residual disease in patients with advanced-stage tumors. 
Adequate and complete initial intervention is among the 
most powerful clinician-driven determinants of  survival 
for women with ovarian cancer; and (3) the above con-
clusions call for widespread and consistent support by 
the medical community and governmental organizations 
in recognising specialty training in gynaecological oncol-
ogy as a necessary component for comprehensive health 
care for women[22]. 
The standard of  therapy in patients with advanced 
ovarian cancer is the surgical exploration of  the pelvis and 
the upper abdomen and a maximum cytoreduction. The 
aim of  surgery is to remove all tumor-infiltrated organs 
including the peritoneum, bowel, spleen, hepatic tissue 
etc., thus surgery is not limited to the pelvis, the omentum 
and the lymph nodes. Bristow et al[23] showed that even 
in patients with un-resectable liver metastasis, optimal 
de-bulking of  extra-hepatic disease is associated with a 
significant survival advantage. Therefore, the intent of  
surgery is not to leave any macroscopic intraabdominal 
disease[24]. In a high percentage of  patients, this aim can 
be reached by an encouraged, ultraradical, consequent, 
multivisceral surgery. Eisenkop et al[24] achieved 85% of  
optimal cytoreduction in a series of  163 patients with 
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stage Ⅲ and Ⅳ ovarian cancer. In our opinion, the limit 
of  resectability can be defined by the extent of  miliaric 
carcinomatosis on the serosa of  the small bowel and 
by the infiltration of  the major abdominal vessels. In 
conclusion, we should answer a crucial question to 
support the role of  cyto-reduction in the management 
of  advanced ovarian cancer: is attainment of  an optimal 
outcome largely related to philosophy and skill of  
the surgeons or does it reflect a less aggressive tumor 
biology? These issues are still being studied and debated 
after more than 20 years. We believe that the better 
understanding of  tumor biology can help in the planning 
of  surgical strategy in cases of  recurrent ovarian cancer, 
but the patient’s general health, the presence of  diffuse 
carcinomatosis, and the surgical philosophy are correlated 
with the achievement of  an optimal surgical outcome.
NOVEL APPROACHES AND THE ROLE 
OF INTRAPERITONEAL CHEMOTHERAPY 
IN THE MANAGEMENT OF ADVANCED 
OVARIAN CANCER
Only about 50% of  patients show a complete clinical 
response to systemic platinum/taxol based chemotherapy, 
and 30% of  them have microscopic metastasis at second 
look surgery. Despite achieving clinical remission after 
completion of  initial treatment, most patients (60%) with 
advanced epithelial ovarian cancer will ultimately develop 
recurrent disease or show drug resistance, and their rate 
of  curability is less than 30%. The recurrence rate ranges 
between 30% and 50% for patients who show no lesion at 
the time of  second look surgery[25]. In these patients, the 
median disease-free survival is only 24 mo. 
These factors are major limitations in treatment of  
patients with ovarian cancer[26]. Different treatment moda-
lities have been attempted to overcome these limits, 
such as secondary cytoreduction, second-line chemo-
therapeutic drugs, high-dose chemotherapy, intraperitoneal 
chemotherapy (IP), radiotherapy, immunotherapy, and 
hormone therapy. In fact, it is conceivable that recurrences 
in platinum-responsive patients might be prevented by 
higher doses of  drugs to eradicate less sensitive clones of  
tumor cells that became resistant to platinum when lower 
doses are given during initial treatment[27].
To date, except for IP chemotherapy, none of  these 
approaches has been found to have a significant impact 
on survival. IP chemotherapy refers to the administra-
tion of  cytotoxic agents directly at the predominant 
disease site: the peritoneal cavity. The rationale is that a 
higher concentration of  cytotoxic drugs and longer du-
ration of  exposure can be achieved while reducing the 
toxicity normally associated with intravenous therapy. In 
fact, cytotoxic drugs administered IP can directly target 
tumor masses confined to the abdominal cavity, thus by-
passing the poor vascularization of  small-volume disease 
and, therefore, increasing peri- and intra tumoral drug 
concentration. Cisplatin can penetrate small-volume tu-
mors to a maximum depth of  1-3 mm; therefore, a ben-
efit of  this schedule can be obtained only for patients 
with microscopic residual disease. By the use of  large 
doses of  intraperitoneal cisplatin, the surface of  the tu-
mor can be exposed to high concentrations of  cisplatin 
with a sufficient amount of  drug leaking into the circula-
tion. Thus, the level of  drug reaching the tumor through 
capillaries is doubled compared with a maximally toler-
ated dose of  cisplatin delivered intravenously[28].
Two large phase Ⅲ trials published in 1996 and 2001 
have documented some outcome advantages for IP ther-
apy[29,30]. Recently, a 3rd randomized trial showed that IP 
chemotherapy provides better long-term outcome than 
Ⅳ drug delivery in patients with advanced ovarian can-
cer[31]. In the United States, the National Cancer Institute 
and the Society of  Gynecologic Oncologists have en-
dorsed the use of  intraperitoneal chemotherapy in recent 
position papers. However, some concerns have been 
raised about the use of  IP therapy: (1) the effectiveness 
of  IP therapy depends on uniform drug distribution. 
It is essential that fluid circulates freely throughout the 
peritoneal cavity. After cytoreductive surgery, the risk of  
IP adhesion formation is increased, which might limit 
the access of  the active drug to the tumor areas; and (2) 
various complications have been attributed to IP cath-
eter, such as infections. 
The intraoperative administration of  intraperitoneal 
chemotherapy has been designed to overcome such ob-
stacles. The use of  intraoperative intraperitoneal chemo-
therapy avoids the pitfalls of  postoperative adhesions 
and inconsistent drug distribution. Overall, intraopera-
tive chemotherapy allows optimal drug distribution to 
all peritoneal surfaces. This produces a regional pharma-
cokinetic advantage with the amount of  drug delivered 
to the tumor greater than that delivered systemically. 
Intraperitoneal hyperthermic chemotherapy (HIPEC) 
is a new treatment modality that is based on increasing 
the sensitivity of  cancer cells to the direct cytotoxic ef-
fect of  chemotherapeutic agents at high temperature 
and increasing the concentration of  chemotherapeutic 
agents that penetrate cancer tissues[32-34]. In fact, it has 
been proved that high temperature damages cancer cell 
membranes and promotes cellular apoptosis by increas-
ing the intracellular calcium concentration and DNA 
fragmentation. Another mechanism is the destabilization 
of  thymidine kinase 1, which is involved in DNA synthe-
sis in cancer cells[35]. At 42℃, hyperthermia is cytotoxic 
by itself, increasing membrane permeability, inhibiting 
DNA repair, and promoting macrophage lysosomal 
exocytosis with consequent apoptosis[36]. The treatment 
modulates the activity of  cytokines[37], and increases the 
antigenicity of  tumor cells by the production of  heat shock 
proteins and the activation of  natural killer cells[38]. In 
conclusion, the biophysical effects of  HIPEC are: mem-
brane protein denaturation, increased vascular perm-
eability, and alterations of  multimolecular complex for 
DNA synthesis and repair. Moreover, the architecture 
of  the vasculature in solid tumors is chaotic, resulting in 
regions with low pH, hypoxia, and low glucose levels. This 
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microenvironment makes solid tumors more susceptible 
to hyperthermia[39]. 
Cisplatin has been shown to penetrate deeper into 
tumor tissue under hyperthermic conditions compared 
to normothermic conditions. At 40-43℃, neoplastic cells 
become more chemo-sensitive due to an enhancement 
of  intracellular concentrations of  drugs and to alterations 
in the DNA repair process, especially for alkylating ag-
ents[40,41]. In addition, it has been shown that these events 
have a greater intensity in cisplatin-resistant rather than 
cisplatin-sensitive ovarian cancer cells lines. Formation 
of  platinum-DNA adducts after cisplatin exposure is 
enhanced in heated cells, thus resulting in relatively greater 
DNA damage[42]. 
The critical point of  this approach is cytoreduction 
down to nodules of  less than few millimetres, to allow 
HIPEC to act. The possible synergy between hyper-
thermia and chemotherapy agents has sparked clinical 
trials utilizing this combination in many disease types. 
With regard to situations analogous with ovarian carci-
noma, in which the disease may be widespread within 
the peritoneal cavity, studies in gastric cancer, malignant 
mesothelioma, appendix cancer, and colorectal cancer 
have shown promising results. A phase Ⅲ randomized 
study of  hyperthermic intraperitoneal chemotherapy 
following cytoreductive surgery compared with traditional 
iv chemotherapy in patients with peritoneal spread of  
colorectal carcinoma showed a statistically significant 
prolongation of  life in the experimental arm [43]. In 
addition, this combined treatment has been suggested as 
the standard of  care for peritoneal dissemination from 
neoplasm of  the appendix[44,45] and diffuse malignant 
peritoneal mesothelioma[46]. With long-term follow-up, 
cytoreductive surgery plus HIPEC is the only treatment 
associated with a cure for these diseases.
EOC is a logical target for directed intraperitoneal 
therapy in combination with heat, and there are reports 
of  clinical studies looking at hyperthermic intraperitoneal 
chemotherapy following surgical debulking in this 
disease[47-56]. In 2001, Hager et al[54] reported that HIPEC 
significantly increased the survival and response rates, 
and improved the quality of  life, in 36 stage Ⅲ and Ⅳ 
ovarian cancer patients who showed resistance to systemic 
chemotherapy. Deraco et al [57] reported that HIPEC 
significantly increased two-year survival to 55% and 
delayed tumor progression in 27 patients with recurrent 
ovarian cancer after extensive surgery to nodules less 
than 2.5 mm in diameter. Nevertheless, the few clinical 
studies looking at HIPEC following surgical debulking 
suffer from some limitations: relatively small numbers of  
patients, retrospective studies, different clinical settings 
and drugs. In fact, published data show that different 
groups of  patients have been often mixed together, in 
terms of  number of  recurrence (persistent, first, second, 
and third), type of  recurrence (single, multiple, and 
carcinosis) and PFI (platinum-sensitive or -resistant). 
More recently, we reported an interesting series on the 
use of  HIPEC and cytoreductive surgery in a specific 
setting of  patients, where ovarian cancer women at their 
first recurrence with a PFI of  at least 6 mo presented to 
a gynecological oncology referral centre[58]. All cases were 
strictly selected before inclusion in the protocol, utilizing 
AGO-DESKTOP Ⅱ criteria for secondary cytoreduction 
and performing an FDG-PET/CT and S-LPS in all cases 
before attempting surgery. The preoperative evaluation 
allowed a complete cytoreduction in 100% of  the patients 
(23 CC-0 and two CC-1), that is an excellent result when 
compared to 50% of  complete cytoreduction shown in a 
recent meta-analysis on secondary surgery[4]. As might be 
expected, this satisfying result was achieved at the cost of  
multiple organ resections, but peri-operative mortality and 
morbidity rates were 0% and 30%, respectively, which are 
well balanced with data reported in the recent literature, 
even if  cytoreductive surgery alone is considered[59]. In 
conclusion, considering the potential advantages of  
HIPEC associated with cytoreductive surgery and the low 
morbidity and mortality rates, such a promising approach 
should be encouraged for long-term survival in platinum-
sensitive recurrent ovarian cancer patients. We await larger 
prospective randomized studies with longer follow-up 
times.
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